Truveris key facts
- Developer of a health information technology platform designed to offer prescription benefit plans.
- Truveris’s last known valuation is $32.0M.
- It has raised $68.7M; the latest was Later Stage VC ($15.0M) in May 2024.
- Notable investors include First Round Capital, Canaan Partners, KBW Ventures, Revelation Partners, McKesson Ventures — 9 tracked in total.
- Status: Privately Held (backing).
- ·Watch Truveris: the Monday email on marks, rounds and moves
Truveris funding rounds
No funding rounds for Truveris are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Truveris valuation
Truveris's last known valuation is $32 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Truveris investors
9 investors are on record for Truveris, including First Round Capital, Canaan Partners, KBW Ventures and Revelation Partners.
About Truveris
Developer of a health information technology platform designed to offer prescription benefit plans. The company's platform provides specific and actionable insights and assists payers of pharmacy benefits, validates claim payment accuracy, ensures regulatory compliance, and manages pharmacy spending with their scalable and automated implement claims analysis engine, enabling payers, brokers, and manufacturers to effectively and efficiently manage the complexity and rising costs of prescription drugs, reduce costs and improve access.
- Sector
- Healthcare
- HQ
- Wilmington, DE, United States
- Founded
- 2009
- Employees
- 93
- Website
- truveris.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Truveris’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.